Sigachi Industries Ltd
Sigachi Industries Ltd. engages in the manufacture and sale of microcrystalline cellulose. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2021-11-15. The firm is engaged in manufacturing cellulose-based excipients for finished dosages in the pharmaceutical industry. The Company’s products include EXCiPACT GMP, SGMP, HACCP and EDQM CEP. The firm's pre-formulated excipients include BARETab PH, BARETab ODT and BARETab Nutra. The company produces MCC in various grades ranging from 15 to 250 microns for the domestic and export markets under the HiCel and AceCel brands. The firm offers Anti-ulcers (Gastrointestinal) Products and their Intermediates. The company operates over three manufacturing units situated in Hyderabad, Jhagadia and Dahej. The firm serves pharmaceutical, food and nutraceuticals, cosmetic and chemical industries. Its international business spreads across 50 countries, including Asia, Australia, American Continent, Europe and the Middle East.
Price Trend & Technical Volume
Daily QuotesPrice Chart (Historical Trend)
Interactive index-style Recharts with entry animations
4V Matrix
Multi-dimensional proprietary scoreValuation Comparison
Intrinsic & Fair Value Multiples* DCF valuation criteria: 2-Stage model: 10% growth rate years 1-5, 10.5% discount rate, 3% terminal growth rate
Community Sentiment
Be the first to voteWhat is your outlook on Sigachi Industries Ltd? Anonymous community voting — click an option to cast or update your vote.
AI Diagnostics Score
Weighted model combining fundamental, technical & growth factors.
- Debt/Equity is within safe range (0.26).
- Piotroski financial solvency score: 3/9.
- Momentum metrics indicate consolidation near key averages.
Historical Returns
Growth Analysis
| Metric | 1-Yr YoY | 3-Yr CAGR | 5-Yr CAGR |
|---|---|---|---|
| Sales | -2.1% | +16.5% | — |
| Profit | -217.5% | — | — |
Institutional Valuation Models & Fundamental Quality Methodology
DesiStocks synthesizes classical institutional valuation models and financial distress frameworks to provide a balanced, multi-dimensional view of Indian equity fundamentals. Review each methodology below to understand its core drivers, appropriate use cases, and inherent assumptions.
Projects operating cash flows minus capital expenditures over a 5-year forecast window, discounted back to present value using the Weighted Average Cost of Capital (WACC). Terminal value assumes a sustainable 4% perpetual growth rate matching India's long-term GDP expansion.
Rooted in classic value investing doctrine: √(22.5 × EPS × Book Value). Graham's formula sets a defensive price ceiling to ensure an investor never pays more than 15x earnings and 1.5x tangible book value simultaneously.
Anchored in Growth at a Reasonable Price (GARP). Equates a fair P/E multiple directly to the sustainable earnings growth rate percentage: Fair Price = EPS × Growth Rate. A PEG below 1.0 signifies potential undervaluation relative to growth.
Nine binary financial tests across profitability (positive ROA, cash flow > net income), balance sheet leverage (declining debt, rising liquidity, zero share dilution), and operational efficiency (improving gross margin and asset turnover). High scores (8–9) confirm robust quality.
Five weighted financial ratios assessing working capital, cumulative profitability, operating leverage, market capitalization, and asset turnover. Proven predictor of balance sheet stress and corporate bankruptcy probability over a 24-month horizon.
Proprietary four-pillar diagnostic framework examining Valuation (multiples vs 5Y history), Value Creation (ROCE spread over WACC cost of capital), Volatility (drawdown containment & beta), and Velocity (operating profit momentum).
All intrinsic valuations and scores are mathematical models generated using publicly available financial statements and historical market disclosures. These calculations do not represent guaranteed future price targets, investment advice, or research analyst buy/sell ratings under SEBI (Research Analysts) Regulations. Always perform independent diligence and consult a licensed financial advisor.